Atelocollagen-mediated systemic DDS for nucleic acid medicines

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Oligonucleotide Therapeutics

Background:

• Oligonucleotide therapy holds great promise but faces challenges in efficient and stable delivery.
• Developing practical drug delivery platforms is crucial for advancing oligonucleotide-based treatments.

Purpose of the Study:

• To evaluate the efficacy of an atelocollagen-mediated system for delivering oligonucleotides in animal disease models.
• To establish a practical platform for systemic oligonucleotide therapy.

Main Methods:

• Complexation of atelocollagen with small interfering RNA (siRNA) and antisense oligodeoxynucleotides into nuclease-resistant nanoparticles.
• Intravenous administration of the atelocollagen-oligonucleotide complexes in animal models.
• Assessment of therapeutic efficacy in tumor metastasis and contact hypersensitivity models.

Main Results:

• Atelocollagen-oligonucleotide complexes demonstrated high stability against nucleases.
• Efficient delivery of oligonucleotides to various organs and tissues, including bone metastases.
• Inhibition of tumor growth in bone and suppression of ear dermatitis following treatment.

Conclusions:

• Atelocollagen serves as an effective carrier for systemic oligonucleotide delivery.
• The atelocollagen-mediated system shows strong potential for practical therapeutic applications in oligonucleotide therapy.
• This delivery system offers a viable strategy for treating diseases like cancer metastasis and inflammatory conditions.